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Abstract
Background: Antimicrobial prophylaxis reduces the incidence of postoperative wound infections especially among
patients undergoing orthopedics surgery. However, there is dearth of information on the clinical effectiveness,
spectrum limitations and practical contextual information on third and fourth generation cephalosporins. The aim
of this study was to evaluate the efficacy and safety of cefepime and ceftriaxone as peri-operative systemic
antimicrobial prophylaxis in elective orthopedic surgery in our center.
Methods: This study was a prospective, randomized, open label comparative clinical study of patients undergoing
elective orthopedic procedures at the Bugando Medical Centre (BMC) between June 2014 and February 2015. Two
hundred thirty participants were enrolled in the study and randomly assigned into Ceftriaxone regimen (group A)
or Cefepime regimen (group B). Participants in ceftriaxone or cefepime group received 50 mg/kg up to 2 g single
dose perioperative intravenous infusion at least 30 min before incision. Both groups were followed for 30 days
using a Center for Disease Control superficial surgical site infection criterion for the outcome. A two-tailed margin
of equivalence was set at 5 % analyzed on the intent to treat.
Results: All 230 participants were subjected to final analysis with no patient being lost to follow-up. Superficial
surgical site infection occurred in 5 out of 117 (4.3 %, 0.6 to 7.9 at 95 % CI) patients receiving cefepime compared
to 3 out of 113 (2.7 %, 0.3 to 5.6 at 95 % CI) among patients receiving ceftriaxone regimen. The absolute difference
of 1.6 % (95 % Confidence Interval: −6.3 to 3.1), equivocally lies outside the 5 % statistically significant margin of
presumed clinical equivalence.
Conclusion: The difference between cefepime and ceftriaxone in preventing SSIs following elective clean
orthopedic surgery was not statistically significant.
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Background
Surgical site infections (SSIs) continue to be a major
source of morbidity and mortality in developing and
resource limited countries despite advances in aseptic
techniques [1–4]. Orthopedic patients especially for
those who require corrective surgical procedures have a
greater risk of surgical site infections [5]. SSIs are im-
portant complications of orthopedic procedures often
associated with prolonged length of hospital stay, high
incidence of readmission, huge treatment costs and low
quality of life [6].
The principles of prophylaxis against post-surgical
infection have been established and the administration
of antibiotics within 60 min prior to surgery is now
widely accepted [7]. The choice of perioperative
prophylactic antibiotics follows the principles that the
selected regimen should target microbial agents com-
monly involved in surgical site contamination and
definite infection. In orthopedics surgery seeding of
the operative site from a distant site of infection can
also occur especially in patients with prosthesis or
other implants [8].
Evidence has shown that a single dose cephalosporin
prophylaxis leads to a significant reduction in the propor-
tion of developing surgical site infections, and is adequate
in orthopedic surgical procedures [9–12]. A latest Cochrane
systematic review reported that perioperative prophylaxis
during the operative management of closed fractures re-
duce infection rates from around 5 % to less than 1 % [13].
Recently, after the introduction of cefepime in
Tanzania, clinicians started prescribing it in the place of
previously favored regimes such as ceftriaxone, penicil-
lins and aminoglycosides [14]. However, at Bugando
Medical Centre (BMC), the prophylactic efficacy of cefe-
pime over other cephalosporins or other prophylactic
regimens remains unknown, especially in our trauma
and orthopedic surgery.
No standard or written guidelines exist in our
centre to direct the choice of effective or appropriate
antimicrobial regimen for use as perioperative
prophylaxis during elective orthopedic surgery. There-
fore, this study was performed to compare the
efficacy of cefepime and ceftriaxone for systemic peri-




This study was a comparative, open label, prospective
randomized clinical trial. It was performed to compare
the efficacy, of a single dose prophylactic cefepime and
ceftriaxone among patients underwent elective orthopedic
surgery at BMC, Mwanza Tanzania.
Study population
The study population included all patients admitted at
the BMC orthopedic wards and planned for elective
orthopedic surgical procedure between June 2014 and
February 2015 [15]. All orthopedic patients between 1
and 70 years of age planned for elective orthopedic sur-
gery were considered eligible. However, patients with
open contaminated fractures, history of any antibiotic
use within 7 days preceding surgery, known history of
hypersensitivity to beta-lactams, immunodeficiency dis-
orders, HIV infection, pregnancy, diabetes or existing in-
fection of soft tissue, bone or at the site of the fracture
were excluded from the study.
Sample size estimation
The sample size was estimated using the formula pub-
lished by Altman [16] and as used by Noordzij et al.
[17]. The expected SSI rate estimates for ceftriaxone and
cefepime were 2.3 % and 1.1 % respectively among pa-
tients as published by Del Rio et al. [18]. The conven-
tional multipliers for alpha = 0.05 and multiplier for
power = 0.90 were used and we considered a pre-study
difference of more than 5 % between the two groups to
be statistically significant. The sample size obtained was
208 patients (a minimum of 104 participants per group)
and 10 % of this estimate was added to cover for non-
response or loss to follow up, thus the required mini-
mum sample size became 230 patients.
Randomization
Participants were assigned to one of two treatment
groups, designated as “A” (ceftriaxone) and “B” (cefepime)
using four digits, randomly generated computer numbers.
Randomization to the two study arms was at 1:1 ratio.
Each patient received 50 mg/kg (maximum 2 g) intraven-
ous antibiotic given within 30 min before surgery. In case
surgery lasted beyond 4 h or blood loss, surpassed
1500 mL the dose was repeated.
Null hypothesis
The treatment difference on the proportion of elective
orthopedic surgery SSI in the two arms should be less or
equal to ± 5 %.
Alternative hypothesis
The treatment difference on the proportion of elective
orthopedic surgery SSI in the two arms should be more
than ± 5 %.
Explanatory variables
Independent variables were demographic data (e.g. age,
sex, and occupation), clinical presentation, ASA classifi-
cation, type of orthopedic surgical procedure and im-
plants used. In addition, duration of procedure, blood
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loss, type of anesthesia, wound closures, placement or
removal of internal or external implants, and use of
drains were also included.
Primary outcome measure
Surgical site infection was the primary end point carried
out between day 3 and 30 after surgery. Two members of
the orthopedic team alien to the study provided surveil-
lance and clinical diagnosis of surgical site infection in the
ward or SOPD. The CDC criteria of wound infection oc-
curring at the incision site within 30 days after surgery
and involving the skin, subcutaneous tissue, or muscle lo-
cated above the fascial layer formed the basis for SSIs sur-
veillance was used [19].
Surveillance continued for 30 days by making tele-
phone calls and if patients reported any symptoms of
wound infection patients were requested to return to the
hospital for re-examination and specimen collection.
Microbiology laboratory studies
Wound discharge or pus were collected from infected
surgical incisions using sterile cotton swabs without
contaminating with skin commensals and was placed in
a sterile bottle with transport media (Oxoid, UK). Col-
lected samples were transported to laboratory within 1 h
after being obtained. In the laboratory, specimens were
registered and processed following standard laboratory
procedures (SOPs) [20].
Isolates were identified using in-house biochemical
tests as previously described [21, 22]. All isolates were
subjected to antimicrobial drug susceptibility testing
using disk diffusion method as stipulated by the Clinical
Laboratory Standard Institute (CLSI) guidelines [23].
Data collection
Data were recorded on three different data sheets coded
as Data Sheets A, B, and C. Data Sheet A focused on
Contact information, socio-demographic information of
the patient, morbid history and preoperative laboratory
test results. The explanatory data captured included: age,
gender, mechanism of injury, time to treatment, medical
history and prior treatments, co-morbidities, smoking,
alcohol use, andrecent history of antibiotic use. The
attending doctor collected on or near the day of admis-
sion this information.
Sheet B contained intra-operative data regarding the
treatments option for each injury, including the dates of
the treatments, types of procedures, operative time, and
blood loss, type of anesthesia, wound closure options,
placement or removal of internal or external implants.
This information on data sheet B was collectedintra-
operatively corroborating with real time medical records
by anesthetic and nursing staff.
Data Sheet C contained postoperative surveillance and
follow-up information regarding progress, and subsequent
treatment outcomes. In addition, the PI and researchassis-
tants did transcribed phone conversations and completed
progress charts during scheduled SOPD clinic visits.
Data management and statistical data analysis
Data were entered and cleaned using SPSS® version 21
(IBM Corporation) and re-assigned into STATA® Version
11 for analysis. The analysis of data involved hypothesis
testing and comparison of study outcomes between cefe-
pime and ceftriaxone groups. A statistical difference was
established for a significant difference in cumulative in-
cidence of surgical site infection between patients under-
going elective orthopedic surgery receiving peri-
operative e ceftriaxone and cefepime regimen. Four
parameters- cumulative incidence, incidence rate, 95 %
confidence intervals and P-values were used to delineate
results. Fisher’s Exact Test and P-value of analyzed data <
0.05 was considered to be statistically significant.
Cumulative incidence was calculated as the proportion
of cases with SSI noted over total number of participants
in each regimen under study. Incidence rate was com-
puted by dividing the number of study subjects mani-
festing wound infection with total person follow-up
days. Proportion test was done to determine the 95 % CI
of the rates of SSI in two arms.
Data were summarized in form of proportions, and
frequency tables, for categorical variables, while mea-
sures of central tendency were used to summarize con-
tinuous variables.
Ethical clearance
This trial did not involve new drugs but only determined
the efficacy of a single dose regime of ceftriaxone and
cefepime, however GCP and Declaration of Helsinki
were observed. The study was cleared by CUHAS/BMC
Research Ethics Committee with certificate no CRE/010/
2014. An informed consent was obtained from partici-
pants after explaining the rationale of the study.
Results
Number of patients recruited
A total of 248 patients who were planned to undergo
elective orthopedic surgery were assessed for eligibility
between June 2014 and February 2015. Fourteen were
excluded for failure to meet the inclusion criteria, while
four candidates declined to consent for enrollment into
the clinical trial. Consequently, 230 patients were re-
cruited and randomized into ceftriaxone (Group A, 113
patients) and cefepime (Group B, 117 patients) as shown
in Fig. 1.
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Demographic characteristics of the study population
There was an even distribution of the participants with
respect to demographic and other baseline characteristics
in group A and group B (p-value >0.05) as shown in
Table 1.
Pre-operative clinical presentation
Even distribution of pre-operative clinical characteris-
tics was observed in both arms except for site of lesion
and time taken before definitive treatment was given
(p-value < 0.05) as seen in Table 2.
Intra-operative clinical presentation
No statistical differences were observed in the distribu-
tion of intra-operative clinical characteristics in both
groups as seen in Table 3.
Clinical outcomes
Increasing tenderness at surgical site after discharge from
ward was reported among 3 (2.6 %) patients in cefe-
pime group and 1 (0.9 %) patient in the ceftriaxone
arm. Four clients in-group B demonstrated fever >
38.5 °C during the follow up period while 112 (99.1 %)
in group A and 112 (95.7 %) in-group B schedule did
not report any event during routine enquiry or follow
up Table 4.
Incidence of SSI in elective surgery
Among 230 clients 8 (3.47 %) developed superficial sur-
gical site infections. The disaggregated incidence in the
ceftriaxone group was 2.7 % [95 % CI 0.3–5.6) compared
to 4.3 % (95 % CI 0.6–7.9) for patients enrolled into the
cefepime group (P = 0.380) as shown in Table 4. The
probability of developing superficial SSI decreased over
time manifested as wound dehiscence and positive cul-
ture as shown in Kaplan Cox and Meier survival graph
(Fig. 2).
Efficacy of cefepime over ceftriaxone regimen
The incidence rate was calculated as person days for both
arms of clinical study. In this study the incidence rate of
superficial surgical site infection were 0.9 and 1.45 per
1000 person days in group A (ceftriaxone) and group B
(cefepime) regimes respectively (p = 0.380) Table 5.
Bacterial isolates
As empirical proof of infection, bacterial isolates were
necessary and useful in the choice of antimicrobial
among patients presenting with clinical features of SSIs.
The bacteriological isolates in the ceftriaxone group
were Staphylococcus aureus, Pseudomonas aeruginosa
and Coagulase negative Staphylococcus. In-group B (ce-
fepime) regimen, bacteriological isolates were Staphylo-
coccus aureus, Coagulase negative Staphylococcus,
Proteus spp., Klebsiella pneumoniae and 1 unidentified
gram negative bacteria.
All bacterial isolates in ceftriaxone and cefepime
groups were sensitive to ciprofloxacin, ceftazidime and
gentamicin. The Proteus spp.isolated was resistant to
ceftazidime, amoxicillin clavulanic acid and Trimetho-
prim/sulphamethaxazole (TMP/SMX).
Discussion
Demographic and clinical characteristics of patients
The contribution of antibiotic single agent perioperative
prophylaxis to reduce SSIs for most surgical procedures
Fig. 1 Flow chart showing disaggregated number of participants
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is established. However, optimal use of prophylactic anti-
microbial agents does not obviate other factors such as
meticulous attention to basic infection-control strategies.
The present study did not define age, gender, or mech-
anism of injury as significant risk factors associated with
SSIs. These findings are in agreement with Maksimovic
et al. [2] and Graf et. al [24] who found no significant as-
sociation in age or gender between case patients and their
matched interventions. However, in a recent Egyptian
study, it was reported age above 68 years to be a risk fac-
tor for SSIs among 93 orthopedic patients [25]
Recently, the contribution of prolonged pre-operative
duration hospital stay of 13.6 ± 1.6 days and duration of
operation beyond 75th percentile for procedure have
been strongly linked to increase SSI in orthopedic sur-
gery (Khaleid et al. [25]. In the present study, there was
a statistically significant difference in participants distri-
bution in two groups regarding time spent in hospital
before treatment and the anatomical site of the lesion.
Despite majority of patients in ceftriaxone group stayed
significantly longer in the hospital before treatment less
SSI was observed in this group. Overwhelmed surgical
systems and resource poor setting may explain pro-
longed hospital stay whereas lower limb lesions pre-
dominate since it is the most common injury incurred
by motorcycle accidents victims in our setting [26].
Incidence of superficial surgical site infection
This study demonstrated that the cumulative incidence
of superficial SSI after intervention among the partici-
pants was comparable to rates detected in some devel-
oping countries [4, 27–29]. While in this study
ceftriaxone arm showed a lower cumulative incidence
compared to cefepime arm, the difference was not statis-
tically significant. These findings are in tandem with
landmark studies and meta-analysis reviews that pegged
effects of a single agent perioperative prophylaxis in re-
duction of SSI incidence rate to a range between 0 to
8 % among patients who underwent elective orthopedic
surgery. Comparatively, and in consideration of cefepime
and ceftriaxone head-to-head non-orthopedic compara-
tive multicenter trial in Parma Italy the study reported
the SSI incidence of 2.3 % for ceftriaxone group and
1.1 % in the cefepime group. However, the difference of
SSIs among 209 participants was not statistically differ-
ent [18]. Using similar methodology in the present study,
the incidence nearly doubled, which speculatively may
be attributed to wound class and target organism select-
ivity in orthopedics compared to biliary surgery.
Table 1 Background epidemiological parameters of patients










Median 29 30 0.3229
IQR 14–40 21–40
Age group
<21 years 40 (35.40 %) 29 (24.79 %) 0.292
21–40 years 48 (42.48 %) 60 (51.28 %)
41–60 years 23 (20.35 %) 24 (20.51 %)
>60 years 2 (1.77 %) 4 (3.42 %)
Sex
Males 77 (68.1 %) 81 (69.2 %) 0.562
Females 36 (31.9 %) 32 (30.8 %)
Level of education
Primary 56 (49.6 %) 56 (47.9 %) 0.859
Secondary 44 (38.9 %) 48 (41.0 %)
Tertiary 9 (8.0 %) 8 (6.8 %)
Informal 4 (3.5 %) 5 (4.3 %)
Occupation
Employed 38 (33.63 %) 39 (33.33 %) 0.095
Unemployed 35 (30.97 %) 50 (42.74 %)
Dependant 40 (35.40 %) 28 (23.93 %)
Mode of Health
Care Financing
Out of Pocket 90 (79.65 %) 91 (77.78 %) 0.729
Health Insurance 23 (20.35 %) 26 (22.22 %)
Table 2 Pre- operative parameters of patients subjected to







N = 113 N = 117
Indication for surgery
Trauma related 91 (80.53 %) 100 (85.47 %) 0.318
Non-Trauma Related 22 (19.47 %) 17 (14.53 %)
Anatomical location of lesion
Upper Limb 44 (38.9 %) 30 (26.6 %) 0.031
Lower limb 69 (61.1 %) 87 (74.4 %)
Time to treatment
Less than 2 weeks 29 (25.7 %) 48 (41.0 %) 0.014
More than 2 Weeks 84 (74.3 %) 69 (59.0 %)
History of antibiotic use
None 84 (74.3 %) 81 (69.2 %) 0.39
More than 7 days 29 (25.7 %) 36 (30.8 %)
Type of elective procedure
Invasive 93 (82.3 %) 104 (88.9 %) 0.154
Non Invasive 20 (17.7 %) 13 (11.1 %)
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However, authors in the Italian study attributed the ap-
parently low SSI incidence to a zwitterionic oxymino β-
lactam amino-thiazole side chain- a chemical peculiarity-
of cefepime rather than other study factors.
The present study also showed a low cumulative SSI
incidence in contrast to the outcomes of recent descrip-
tive studies, which reported high SSIs cumulative inci-
dence within disaggregated wound class. Recently in
Egypt, Khaleid et al. [25] reported an cumulative ortho-
pedic SSI incidence rate of 25.8 % (4.1 % in clean
wounds). More so, Maksimovic et al. [2] and Graf et al.
[24] reported an overall orthopedic SSI incidence of
22.7 %(13.2 % in clean wounds) and 22.5 % respectively
in their studies. These studies among many other rea-
sons attributable to higher incidences of orthopedic SSI
reported failed tostate or show whether the researchers
used perioperative prophylaxis among the participants.
Comparison of single dose efficacy between cefepime
and ceftriaxone
This study showed a lower incidence rate of SSIs per
1000 days in ceftriaxone group and nearly twice the rate
in cefepime group, although the difference was not sta-
tistically significant. The difference in the incidence rate
per 1000 days in the cefepime group could not be attrib-
uted or explained on theoretical grounds or its molecu-
lar profile -as a fourth generation cephalosporins the
same as speculated by Yeap et al. [30]. The spectrum dif-
ferences may not explain the difference since both have
a near preponderance to gram-negative organism.
The Incidence Rate Ratio of less than 1.0 was observed
in this study and underscored an overall picture of sub-
stantial effect of cefepime and ceftriaxone in reducing
the incidence of clean orthopedic surgical site infection,
despite of spectrum and selectivity limitations. Other
studies conducted involved comparison between second
or third generation cephalosporins and documented
similar trends on the reduction of SSI incidence rate in
orthopedic surgery [8, 31, 32]. However, there might be
fewer studies published comparing cefepime with other
generations of cephalosporins, despite its documented
use as perioperative prophylaxis during orthopedic sur-
gery [3, 30].
Ceftriaxone and cefepime are both known to have
excellent bioavailability and in this study, a single dose
of 50 mg/kg in pediatric population and up to 2 g intra-
venous infusion among adults was given optimally. The
cost implication between cefepime and ceftriaxone was
Table 4 Selected post-operative characteristics in patients sub-






N = 113 N = 117
Increasing tenderness
Absent 111 (98.23 %) 113 (96.58 %) 0.81
Present 1 (0.9 %) 3 (2.6 %)
Indeterminate 1 (0.9 %) 1 (0.9 %)
Morbid fever
Absent 112 (99.12 %) 112 (95.73 %) 0.122
Present 0 (0.00 %) 4 (3.43 %)
Indeterminate 1 (0.9 %) 1 (0.9 %)
0 0
Wound dehiscence
Present 3 (2.65 %) 5 (4.27 %) 0.380
Absent 110 (97.35 %) 112 (95.73 %)
Occupied Bed Days
1–5 days 68 (60.2 %) 58 (49.6 %) 0.211
6–10 days 43 (38.0 %) 45 (38.5 %)
11–15 days 2 (1.80 %) 13 (11.1 %)
Primary outcome (SSI)
Absent 110 (97.35 %) 112 (95.73 %) 0.380
Present 3 (2.65 %) 5 (4.27 %)
Table 3 Selected intra-operative considerations of patients







N = 113 N = 117
Hemoglobin Level
Mean 11.6 g/dl 11.3 g/dl 0.577
Range 6–17.2 g/dl 5.8–16 g/dl
SDEV 2.17 g/dl 2.10 g/dl
Timing of prophylaxis [within]
<15 min 65 (56 %) 57 (48.7 %) 0.408
>16– < 30 min 43 (38.0 %) 54 (46.2 %)
>31– < 45 min 5 (6.0 %) 6 (5.1 %)
>46 < 60 min 0 0
Approximate blood loss
Less than 400 ml 93 (82.3 %) 88 (75.2 %) 0.189
More than 400 ml 20 (17.7 %) 29 (24.20 %)
Duration of operation [within]
<1 h 60 (53.1 %) 58 (49.6 %) 0.864
2 h 43 (38.1 %) 45 (38.5 %)
3 h 9 (8.0 %) 13 (11.1 %)
4 or More hours 1 (0.8 %) 1 (0.8 %)
ASA Classification
ASA 1 105 (92.92 %) 102 (87.18 %) 0.116
ASA 2 7 (6.19 %) 15 (12.82 %)
ASA 3 1 (0.88) 0.00
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vast and at the time of this study, the cost of 2 g ceftri-
axone was USD 1.20 compared to USD 12.80 (ten times
less) for 2 g of Cefepime. Therefore, the acquisition cost
of ceftriaxone was quite substantially lower than cefe-
pime as a single dose prophylaxis.
The findings also compares well to a Cost Benefit
Analysis study by Mazza [33] involving 477 consecutive
patients who received ceftriaxone before undergoing
orthopedic surgery which reported that a single dose
ceftriaxone given prophylactically was a cost-effective
measure compared to placebo based on infection inci-
dence and length of hospital stay.
The etiological agents of superficial SSI in ceftriaxone and
cefepime groups
In the present study, it was observed that the predomin-
ant organisms causing SSIs after clean procedures in cef-
triaxone group were Staphylococcus aureus, Coagulase-
negative staphylococci, andPseudomonas aeruginosa.
While in cefepime regimen, bacteriological isolates
were Staphylococcus aureus, Coagulase negative
Staphylococcus, Proteus spp., and Klebsiella pneumo-
niae. These findings were congruent with studies con-
ducted at BMC by Mawalla et al. [1] and Khaleid et al.
[25]. A similar observation was made by USNational
Healthcare Safety Network, January 2006-October 2007
while reporting on distribution of pathogens related to
orthopedic surgery [34].
The isolation of Staphylococcus aureus among both
study groups is in agreement with observations made
by the New York State 2009 report where Staphylo-
coccus aureus accounted for 59.8 % of total isolates
in orthopedic surgical site infections [35]. A possible
explanation for Staphylococcus aureus being a
dominant cause ofwound infection in orthopedic
surgeryis generally correlated to admission from a
healthcare facility and nasal carriage of Staphylococ-
cus aureus [36].
During this study infection due to other Staphylococ-
cus spp., isolates had a late presentation post opera-
tively concurrently with Pseudomonas aeruginosa; a
trend also noted by Moss et al. [37]. The drug sensitiv-
ity and resistance pattern of bacterial isolates did not
differ among groups and were broadly resistant to β-
lactams, and were all sensitive to gentamicin and
ciprofloxacin.
Conclusion
Though relatively more SSIs were observed when single
dose of cefepime was used for prophylaxis in elective
orthopedic surgery compared to ceftriaxone this was not
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Fig. 2 Kaplan-Cox-Meier probability estimates of developing (surviving) superficial surgical site infection in elective orthopedic surgery a:
Ceftriaxone, b Cefepime





‘000 person days IR IRR (95 % CI) P- value
Group A 113 3 3324 0.9 0.62 (0.26–1.37) 0.318
Group B 117 5 3429 1.5
IR Incidence Rate (i.e. number per 1000 person days), IRR Incidence Rate Ratio
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negative bacteria depicting resistance to β-lactam based
antibiotics are the dominant etiological agents causing
superficial surgical infection in elective orthopedic sur-
gery at BMC.
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